Evidence map›Paper›PMID 15940345›Full record

ReviewActa biochimica Polonica2005

Targeting site-specific chromosome integration.

Patricia Nuno-Gonzalez, Hsu Chao, Kazuhiro Oka

Abstract readReview
In one paragraph

Review in Acta biochimica Polonica, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Patricia Nuno-GonzalezDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
Hsu Chao
Kazuhiro Oka

Funding

Novel Gene Therapy using Helper-Dependent AdenovirusR01HL073144 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI OKA, KAZUHIRO · 2003 to 2006
$1.0M
NHLBI NIH HHS HL073144NHLBI NIH HHS R01 HL073144
6 · The paper itself

Abstract

The concept of gene therapy was introduced with great promise and high expectations. However, what appeared simple in theory has not translated into practice. Despite some success in clinical trials, the research community is still facing an old problem: namely, the need for a vector that can deliver a gene to target cells without adverse events while maintaining a long-term therapeutic effect. Some of these challenges are being addressed by the development of hybrid vectors which meld two different viral systems to incorporate efficient gene delivery and large cloning capacity with site-specific integration. The two known systems that integrate genes into specific sites in mammalian genomes are the adeno-associated virus and phage integrases. Recent experiments with hybrid vectors incorporating both of these systems are encouraging. However, extensive research should be directed towards the safety and efficacy of this approach before it will be available for gene therapy.

Indexed as

AnimalsDependovirusGenetic TherapyGenetic VectorsHumansIntegrasesViral ProteinsIntegrasesViral Proteins

Identifiers

PMID15940345
PMCPMC1360607

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.